ScreenerHero

PHAT Phathom Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · phathompharma.com
6.810USD+0.44%Mkt Cap: 550.94M $P/E: —

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III cli…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap550.94M USD
Enterprise Value918.05M USD
Revenue (TTM)239.66M USD
Gross Profit152.51M USD
Net Income (TTM)-221.25M USD
Revenue/Share3.06 USD
Last Price6.810 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees371
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)6.30
PEG—
EV/EBITDA-22.88
EV/Revenue3.83
P/S2.29
P/B-1.58
EPS (TTM)-1.26
EPS (Forward)1.08
52W Range
6.5202% of range18.31
52W High18.31 USD
52W Low6.520 USD
Profitability
Gross Margin87.09%
Oper. Margin-5.34%
EBITDA Margin-16.75%
Profit Margin-126.35%
ROE50.49%
ROA-85.37%
Growth
Revenue Growth88.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-166.78M USD
CapEx (TTM)229.00K USD
FCF Margin-13.61%
FCF Yield-5.92%
Net Debt369.55M USD
Net Debt/EBITDA-9.21
Balance Sheet
Debt/Equity-0.48
Current Ratio1.92
Quick Ratio1.82
Book Value/Sh-4.30 USD
Cash/Share2.26 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)20.45 USD
Upside (mean)+200.4%
Target Range10.00 USD – 29.00 USD
10.00+200.4% to mean29.00
# Analysts11
Ownership
Shares Out.80.90M
Float65.29M
Insiders4.66%
Institutions92.31%
Short Interest
Short Ratio9.6d
Short % Float13.21%
Short % Out.12.56%
Shares Short10.16M
Short (prev mo.)11.77M
Technical
SMA 508.619 (-21.0%)
SMA 20011.36 (-40.1%)
Beta0.50
S&P 52W Chg16.45%
Avg Vol (30d)1.20M
Avg Vol (10d)1.29M
Technical Indicators
RSI (14)32.5
MACD-0.6226
MACD Signal-0.5952
MACD Hist.-0.0274
BB Upper9.443 USD
BB Middle7.704 USD
BB Lower5.965 USD
BB Width45.15%
ATR (14)0.4548 USD
Vol Ratio (20d)1.25x